Chimeric Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHM.AX research report →
Price Chart
About the company
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies.
- CEO
- Rebecca McQualter
- IPO
- 2021
- Employees
- 3
- HQ
- Carlton, VIC, AU
Get TickerSpark's AI analysis on CHM.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $820.86K
- P/E
- -0.04
- PEG
- -0.00
- P/S
- 0.23
- P/B
- -0.22
- EV/EBITDA
- 0.20
- Div Yield
- 0.00%
- Gross Margin
- 74.47%
- Op Margin
- -458.31%
- Net Margin
- -420.80%
- ROE
- 2844.96%
- ROIC
- 993.55%
Latest fiscal year · YoY change
- Revenue
- $3.97M-46.8%
- Gross Profit
- $3.12M-58.1%
- Op Income
- $-15,111,460
- Net Income
- $-10,430,424+16.8%
- EPS
- $-0.77+57.2%
- OCF Growth
- +3.5%
- FCF Growth
- -72044.3%
- 52W High
- $0.40
- 52W Low
- $0.01
- 50D MA
- $0.05
- 200D MA
- $0.17
- Beta
- 0.71
- RSI (14)
- 23
- Avg Volume
- 391.58K
No earnings-call transcripts are available for CHM.AX yet.
- Free Float
- 63.9%
- Shares Outstanding
- 41.04M
- Float Shares
- 26.23M
Our CHM.AX coverage
Recent articles, reports, and earnings notes.
No research on CHM.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CHM.AX report →Chimeric Therapeutics secures FDA Orphan Drug Designation for CHM CDH17 in gastric cancer
proactiveinvestors.com · Dec 8
Imugene secures FDA backing for Azer-cel registration pathway
proactiveinvestors.com · Dec 8
Kairos Minerals secures mining agreement with Nyamal Aboriginal Corporation for Mt York Gold Project
proactiveinvestors.com · Dec 8
Chimeric Therapeutics receives $4.5 million R&D tax incentive refund
proactiveinvestors.com · Nov 24
Altech draws interest from top-tier battery manufacturer as Silumina Anodes™ hit 1,000-cycle mark
proactiveinvestors.com · Nov 24
Vaultz completes Xapo Bank onboarding
proactiveinvestors.com · Nov 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.